title: Cost-Effectiveness Analysis of Testing for Brca Mutations in Women Diagnosed with Ovarian Cancer and their Female First-Degree Relatives: A Uk Health Service Perspective.
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: M
authors.initials: M
authors.lastname: Dyer
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: W
authors.initials: W
authors.lastname: Vereecken
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: J
authors.initials: J
authors.lastname: Worrall
authors.affiliation: Institute of Cancer Research, London, UK.
authors.forename: A
authors.initials: A
authors.lastname: George
authors.affiliation: Institute of Cancer Research, London, UK.
authors.forename: N
authors.initials: N
authors.lastname: Rahman